IRCT20200105046010N111招募中Unknown
In-vivo Bioequivalence Study of Ibrutinib 140 mg capsule of The Test Drug (ACTLOUVIKA®, 140 mg ., Actero Pharma, Iran) in Compared with The Reference Drug (IMBRUVICA® 140 mg ., Jenssen Inc. Swiss) In Iranian Healthy Volunteers
Actro Middle East Pharmaceutical Co0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-30)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Ibrutinib
研究者
相似试验
招募中
Unknown
Bioequivalence study of Ibrutinib 140 mgIRCT20200105046010N78Tabriz University of Medical Sciences24
尚未招募
不适用
Study of absorption and elimination rate of Ibrutinib 140 -mg Capsules in comparison with Ibrutinib brand capsules (Imbruvica®)IRCT20200407046981N43Kimia pharmaceutical Co24
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsEUCTR2015-005105-36-CZPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-PLPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005105-36-ITPHARMACYCLICS, INC.74